Aeterna Zentaris Inc. (NASDAQ:AEZS)’s share price fell 1.3% during trading on Monday . The company traded as low as $3.63 and last traded at $3.67, with a volume of 73,150 shares. The stock had previously closed at $3.72.

A number of research firms have commented on AEZS. Maxim Group reissued a “buy” rating and issued a $11.00 price objective on shares of Aeterna Zentaris in a research note on Wednesday, June 15th. Canaccord Genuity reissued a “buy” rating and issued a $9.00 price objective on shares of Aeterna Zentaris in a research note on Tuesday, August 23rd. HC Wainwright reissued a “buy” rating and issued a $12.00 price objective on shares of Aeterna Zentaris in a research note on Sunday, July 10th. Finally, Zacks Investment Research raised Aeterna Zentaris from a “hold” rating to a “buy” rating and set a $4.00 price objective on the stock in a research note on Monday, August 15th.

The stock’s market cap is $36.08 million. The stock’s 50-day moving average is $3.51 and its 200 day moving average is $3.51.

Aeterna Zentaris (NASDAQ:AEZS) last posted its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.71) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.82) by $0.11. On average, equities research analysts forecast that Aeterna Zentaris Inc. will post ($2.61) EPS for the current fiscal year.

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.